ProQR announces Q3 2025 results and update

ProQR Therapeutics N.V. has filed a Form 6-K furnishing unaudited financial statements for the three and nine-month periods ended September 30, 2025, and a related press release.

Accepted by SEC EDGAR 11/06/2025 - 07:00 AM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

ProQR Therapeutics N.V. has filed a Form 6-K furnishing unaudited financial statements for the three and nine-month periods ended September 30, 2025, and a related press release. The press release, titled “ProQR Announces Third Quarter 2025 Operating and Financial Results,” also provides a business update.

The information in this report, including the exhibits, is incorporated by reference into ProQR’s existing shelf registration statements on Form F-3. This links the latest quarterly financial and operating information directly to ProQR’s current securities registration framework.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ProQR Therapeutics (PRQR) disclose in this Form 6-K?

ProQR Therapeutics furnishes unaudited financial statements and a press release covering the three and nine-month periods ended September 30, 2025. The press release provides third quarter 2025 operating and financial results along with a business update, giving investors current performance and operational context.

Which financial periods are covered in ProQR (PRQR) November 6, 2025 update?

The filing covers ProQR’s unaudited financial statements for the three and nine-month periods ended September 30, 2025. It also includes a press release announcing third quarter 2025 operating and financial results, ensuring consistent reporting for both the quarter and year-to-date performance period.

How is the November 6, 2025 ProQR (PRQR) information used in existing registrations?

ProQR explicitly incorporates the information in this Form 6-K into its Form F-3 registration statements. This ties the latest unaudited financials and business update to its active shelf registrations, helping keep offering-related disclosure aligned with current quarterly performance data.

What exhibits are attached to ProQR Therapeutics (PRQR) Form 6-K?

The Form 6-K includes two key exhibits: unaudited financial statements for the three and nine-month periods ended September 30, 2025 (Exhibit 99.1), and a November 6, 2025 press release announcing third quarter 2025 operating and financial results (Exhibit 99.2) with a business update.

Who signed ProQR Therapeutics (PRQR) November 6, 2025 Form 6-K?

The Form 6-K was signed on behalf of ProQR Therapeutics N.V. by Dennis Hom, the company’s Chief Financial Officer. This signature confirms the company’s authorization of the submission of the unaudited financial statements and the related third quarter 2025 press release exhibits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

November 6, 2025

Commission File Number: 001-36622

PROQR THERAPEUTICS N.V.

Zernikedreef 9

2333 CK Leiden

The Netherlands

Tel: +31 88 166 7000

(Address, Including ZIP Code, and Telephone Number,

Including Area Code, of Registrant’s Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

Furnished as Exhibit 99.1 to this Report on Form 6-K are the unaudited financial statements of ProQR Therapeutics N.V. (the “Company”) for the three and nine-month periods ended September 30, 2025, and furnished as Exhibit 99.2 to this Report on Form 6-K is a press release of ProQR Therapeutics N.V. dated November 6, 2025, announcing the Company’s results for the three and nine-month periods ended September 30, 2025.

On November 6, 2025, the Company issued a press release titled, “ProQR Announces Third Quarter 2025 Operating and Financial Results,” announcing the Company’s results for the three and nine-month periods ended September 30, 2025 and providing a business update. A copy of this press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

ProQR hereby incorporates by reference the information contained herein into ProQR’s registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, File No. 333-263166 and File No. 333-285767).

INDEX TO EXHIBITS


Number		Description

99.1		Unaudited financial statements of ProQR Therapeutics N.V. for the three and nine-month periods ended September 30, 2025.

99.2		Press Release of ProQR Therapeutics N.V. dated November 6, 2025, announcing the Company’s results for the three and nine-month periods ended September 30, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	PROQR THERAPEUTICS N.V.


Date: November 6, 2025	By:	/s/ Dennis Hom
		Dennis Hom
		Chief Financial Officer

Source: View Original Filing on SEC EDGAR